Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Manabu Akazawa, Daisuke Shima, Takahiro Sato, Emi Shoji, Michael LoPresti & Ryosuke Nishi. (2022) Perception of Adherence to Daily Human Growth Hormone Treatments Among Pediatric and Adolescent Patients in Japan: A Cross-Sectional Survey of Physicians and Caregivers. Patient Preference and Adherence 16, pages 3081-3094.
Read now
Read now
Tracy J Sims, Kristina S Boye, Susan Robinson & Tessa Kennedy-Martin. (2022) Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors. Patient Preference and Adherence 16, pages 1919-1939.
Read now
Read now
Bradley S Miller & Kevin C J Yuen. (2022) Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. Drug Design, Development and Therapy 16, pages 2055-2066.
Read now
Read now
Jun Inaishi & Yoshifumi Saisho. (2022) Exenatide Once Weekly for Management of Type 2 Diabetes: A Review. Clinical Pharmacology: Advances and Applications 14, pages 19-26.
Read now
Read now
Jane Loftus, Yong Chen, Jose Ma. J. Alvir, Lei Chi, Shibasish Dasgupta, Anu Gupta & Michael P. Wajnrajch. (2021) Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency. Current Medical Research and Opinion 37:12, pages 2141-2150.
Read now
Read now
Tracey Weiss, Richard D Carr, Sampriti Pal, Lingfeng Yang, Baanie Sawhney, Robert Boggs, Swapnil Rajpathak & Kristy Iglay. (2020) Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Preference and Adherence 14, pages 2337-2345.
Read now
Read now
Scott A. Coon, Erica F. Crannage, Lara C. Kerwin & Justinne E. Guyton. (2018) Semaglutide once-weekly: improved efficacy with a new safety warning. Expert Review of Clinical Pharmacology 11:11, pages 1061-1072.
Read now
Read now
Robert S. Busch & Michael P. Kane. (2017) Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate Medicine 129:7, pages 686-697.
Read now
Read now
Stephen L. Aronoff. (2017) Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. Postgraduate Medicine 129:2, pages 231-241.
Read now
Read now
Eric P. Velazquez, Bradley S. Miller & Kevin C.J. Yuen. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products. Expert Review of Endocrinology & Metabolism 0:0.
Read now
Read now
Articles from other publishers (48)
Juliana M. Bue-Valleskey, Christof M. Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt & Juan P. Frias. (2023) Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care 46:5, pages 1060-1067.
Crossref
Crossref
Tsvetelina H. Baryakova, Brett H. Pogostin, Robert Langer & Kevin J. McHugh. (2023) Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery 22:5, pages 387-409.
Crossref
Crossref
Tim Heise, Jenny Chien, John M. Beals, Charles Benson, Oliver Klein, Julie S. Moyers, Axel Haupt & Edward John Pratt. (2023) Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes. Diabetes, Obesity and Metabolism 25:4, pages 1080-1090.
Crossref
Crossref
Juan Frias, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Kristen Syring, Paula Wullenweber, Axel Haupt & Christof Kazda. (2023) Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. The Lancet Diabetes & Endocrinology 11:3, pages 158-168.
Crossref
Crossref
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz & Miguel Ángel Rubio-Herrera. (2022) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine 12:1, pages 145.
Crossref
Crossref
Jane Loftus, Andrew Yaworsky, Carl L. Roland, Diane Turner-Bowker, Megan McLafferty, Sylvia Su & Roger E. Lamoureux. (2022) Experience of switching from a daily to a less frequent administration of injection treatments. PLOS ONE 17:11, pages e0278293.
Crossref
Crossref
Andrew P. Demidowich, Kristine Batty & Mihail Zilbermint. (2022) Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. Diabetes Spectrum 35:4, pages 440-451.
Crossref
Crossref
Julie S. Moyers, Ryan J. Hansen, Jonathan W. Day, Craig D. Dickinson, Chen Zhang, Xiaoping Ruan, Liyun Ding, Robin M. Brown, Hana E. Baker & John M. Beals. (2022) Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. Journal of Pharmacology and Experimental Therapeutics 382:3, pages 346-355.
Crossref
Crossref
Bradley S. Miller. (2022) What do we do now that the long-acting growth hormone is here?. Frontiers in Endocrinology 13.
Crossref
Crossref
Nimer S. Alkhatib, Abdulaali R. Almutairi, Omar S. Alkhezi, Osama M. Alfayez, Majed S. Al Yami & Omar A. Almohammed. (2022) Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharmaceutical Journal 30:4, pages 433-439.
Crossref
Crossref
Yoo Chun Kim, Henry T. Hsueh, Matthew D. Shin, Cynthia A. Berlinicke, Hyounkoo Han, Nicole M. Anders, Avelina Hemingway, Kirby T. Leo, Renee Ti Chou, HyeYoung Kwon, Matthew B. Appell, Usha Rai, Patricia Kolodziejski, Charles Eberhart, Ian Pitha, Donald J. Zack, Justin Hanes & Laura M. Ensign. (2021) A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells. Drug Delivery and Translational Research 12:4, pages 826-837.
Crossref
Crossref
Yi Tang, Xiaohui Pan, Ge Peng & Nanwei Tong. (2022) Weight Loss and Gastrointestinal Hormone Variation Caused by Gastric Artery Embolization: An Updated Analysis Study. Frontiers in Endocrinology 13.
Crossref
Crossref
Dirk Schürmann, Deanne Jackson Rudd, Andrea Schaeffer, Inge De Lepeleire, Evan J. Friedman, Martine Robberechts, Saijuan Zhang, Yang Liu, Bhargava Kandala, Christian Keicher, Martin Däumer, Jörg Hofmann, Jay A. Grobler, S. Aubrey Stoch, Marian Iwamoto & Wendy Ankrom. (2022) Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. JAIDS Journal of Acquired Immune Deficiency Syndromes 89:2, pages 191-198.
Crossref
Crossref
Julio Rosenstock & Stefano Del Prato. (2022) Basal weekly insulins: the way of the future!. Metabolism 126, pages 154924.
Crossref
Crossref
Li Yang, Yao Yang, Hongzhong Chen, Lin Mei & Xiaowei Zeng. (2022) Polymeric microneedle‐mediated sustained release systems: Design strategies and promising applications for drug delivery. Asian Journal of Pharmaceutical Sciences 17:1, pages 70-86.
Crossref
Crossref
Erin R. Weeda, Alyssa K. Muraoka, Matthew D. Brock & Jessica M. Cannon. (2021) Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis. International Journal of Clinical Practice 75:9.
Crossref
Crossref
Kevin Fernando, Stephen C. Bain, Patrick Holmes, Philip Newland Jones & Dipesh C. Patel. (2021) Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review. Diabetes Therapy 12:9, pages 2267-2288.
Crossref
Crossref
Jay S. Skyler. (2021) Weekly Insulin Becoming a Reality. Diabetes Care 44:7, pages 1459-1461.
Crossref
Crossref
Baptist Gallwitz & Francesco Giorgino. (2021) Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Frontiers in Endocrinology 12.
Crossref
Crossref
Juris J. Meier. (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in Endocrinology 12.
Crossref
Crossref
Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, Grace Auld, Sonia Gandhi & Thomas Foltynie. (2021) The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs & Aging 38:5, pages 355-373.
Crossref
Crossref
Michael A. Nauck, Daniel R. Quast, Jakob Wefers & Juris J. Meier. (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism 46, pages 101102.
Crossref
Crossref
Akshay B. Jain, Amar Ali, Juan J. Gorgojo Martínez, Irene Hramiak, Ketan Kavia, Sten Madsbad, Louis Potier, Ben D. Prohaska, Jodi L. Strong & Tina Vilsbøll. (2020) Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice 75:2.
Crossref
Crossref
Ulf Helwig, Karel Kostev & Carsten Schmidt. (2021) Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany. Journal of Clinical Gastroenterology 55:1, pages e1-e7.
Crossref
Crossref
Daniella Balduino Victorino, Mariana Nejm, Marcia Guimarães-Marques, Fulvio Alexandre Scorza & Carla Alessandra Scorza. (2021) Repurposing GLP-1 Receptor Agonists for Parkinson’s Disease: Current Evidence and Future Opportunities. Pharmaceutical Medicine 35:1, pages 11-19.
Crossref
Crossref
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales & Carlos Campos. (2020) Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes 38:4, pages 390-402.
Crossref
Crossref
Dhiren Patel. (2020) Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 45:S1, pages 28-42.
Crossref
Crossref
Ji Hyun Chun & Amy Butts. (2020) Long-acting GLP-1RAs. Journal of the American Academy of Physician Assistants 33:S8, pages 3-18.
Crossref
Crossref
Iakovos Avramidis, Athanasia Apsemidou, Antigoni Z. Lalia, Nikolaos Petridis, Euangelos Tourtouras, Georgios Kalopitas & Georgios Pilianidis. (2020) Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes. Clinical Diabetes 38:3, pages 248-255.
Crossref
Crossref
Stefano Del Prato, Jahoon Kang, Michael E. Trautmann, John Stewart, Christopher H. Sorli, Michael Derwahl, Alfonso Soto & Kun‐Ho Yoon. (2020) Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study. Diabetes, Obesity and Metabolism 22:7, pages 1176-1186.
Crossref
Crossref
Vincent Martin, Karen Hamrick Samaan, Sheena Aurora, Eric M. Pearlman, Chunmei Zhou, Xiaoping Li & Robert Pallay. (2020) Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review. Advances in Therapy 37:5, pages 2034-2049.
Crossref
Crossref
B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Crossref
Julio Rosenstock, Christopher H. Sorli, Michael E. Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart & Kun-Ho Yoon. (2019) Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes Care 42:9, pages 1733-1741.
Crossref
Crossref
Alex Abramson, Florencia Halperin, Jane Kim & Giovanni Traverso. (2019) Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide. Journal of Pharmaceutical Sciences 108:9, pages 3138-3145.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2019) Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation 39:8, pages 805-819.
Crossref
Crossref
Clifford R. Weiss, Godwin O. Abiola, Aaron M. Fischman, Lawrence J. Cheskin, Jay Vairavamurthy, Brian P. Holly, Olaguoke Akinwande, Franklin Nwoke, Kalyan Paudel, Stephen Belmustakov, Kelvin Hong, Rahul S. Patel, Eun J. Shin, Kimberley E. Steele, Timothy H. Moran, Richard E. Thompson, Taylor Dunklin, Harvey Ziessman, Dara L. Kraitchman & Aravind Arepally. (2019) Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. Radiology 291:3, pages 792-800.
Crossref
Crossref
Bruno Guerci, Neha Chanan, Simarjeet Kaur, Juan Guillermo Jasso-Mosqueda & Elisheva Lew. (2019) Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes. Diabetes Therapy 10:2, pages 437-449.
Crossref
Crossref
Anna Y. Zhou & Jennifer M. Trujillo. (2018) Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices. Diabetes Spectrum 31:4, pages 359-366.
Crossref
Crossref
Davida F. Kruger. (2018) Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective. Journal of the American Association of Nurse Practitioners 30:1, pages S43-S52.
Crossref
Crossref
Melissa Magwire. (2018) Once-weekly glucagon-like peptide-1 receptor agonists: An overview. Journal of the American Association of Nurse Practitioners 30:1, pages S2-S3.
Crossref
Crossref
Deborah Hinnen. (2018) Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. Journal of the American Association of Nurse Practitioners 30:1, pages S4-S11.
Crossref
Crossref
Liana K. BillingsYehuda HandelsmanMichael HeileDoron SchneiderKathleen Wyne. (2018) Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S30-S41.
Crossref
Crossref
Hitoshi Ishii, Hiroki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri & Yasuhiro Akai. (2018) Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Therapy 9:3, pages 1001-1019.
Crossref
Crossref
Charalampos Tzanetakos, Alexandra Bargiota, Georgia Kourlaba, George Gourzoulidis & Nikos Maniadakis. (2017) Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical Drug Investigation 38:1, pages 67-77.
Crossref
Crossref
Gagik R. Galstyan, Evgeniya A. Karataeva & Ekaterina A. Yudovich. (2017) Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes mellitus 20:4, pages 286-298.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy 8:2, pages 335-353.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy 8:2, pages 321-334.
Crossref
Crossref
Yingying Pan, Siwei Shi, Xun Lao, Jinlong Zhang, Shiming Tan, Zirong Wu & Jing Huang. (2017) A novel GLP-1 analog, a dimer of GLP-1 via covalent linkage by a lysine, prolongs the action of GLP-1 in the treatment of type 2 diabetes. Peptides 88, pages 46-54.
Crossref
Crossref